Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Abbott Laboratories (Pakistan) Limited

Capitalization 83.42B 299M 259M 234M 224M 407M 27.59B 421M 2.79B 1.11B 13.18B 1.12B 1.1B 47.59B P/E ratio 2023 *
-
P/E ratio 2024 23.2x
Enterprise value 83.42B 299M 259M 234M 224M 407M 27.59B 421M 2.79B 1.11B 13.18B 1.12B 1.1B 47.59B EV / Sales 2023 *
-
EV / Sales 2024 -
Free-Float
16.36%
Yield 2023 *
-
Yield 2024 -
1 day-1.27%
1 week-9.89%
Current month-17.25%
1 month-27.88%
3 months-16.75%
6 months-27.79%
Current year-18.86%
1 week 822.29
Extreme 822.29
900
1 month 822.29
Extreme 822.29
1,181
Current year 822.29
Extreme 822.29
1,274
1 year 790
Extreme 790
1,304
3 years 330
Extreme 330
1,310
5 years 330
Extreme 330
1,310
10 years 302.1
Extreme 302.1
1,310
Manager TitleAgeSince
Chief Executive Officer - 2016-03-31
Director of Finance/CFO - 2019-10-31
Chief Tech/Sci/R&D Officer - 2011-05-31
Director TitleAgeSince
Director/Board Member - 2009-02-28
Director/Board Member - 2014-06-03
Chairman - 2022-05-29
Change 5d. change 1-year change 3-years change Capi.($)
-1.27%-9.89%-19.89%+112.55% 302M
-2.26%-0.61%+18.91%+210.22% 893B
-0.39%+1.01%+48.63%+59.65% 586B
-1.01%-3.00%+6.28%+50.54% 403B
-0.62%-9.47%+3.55%+20.69% 338B
-0.83%-2.78%+23.30%+34.27% 301B
-0.33%-3.19%+25.47%+61.94% 297B
-0.26%-0.14%+24.17%+7.63% 287B
-2.61%+0.05%+17.69%+61.40% 204B
-0.54%+0.05%+27.39%+82.65% 181B
Average -0.75%-2.52%+17.55%+70.15% 348.95B
Weighted average by Cap. -0.46%-1.79%+22.69%+88.39%

Financials

2023 2024
Net sales 55.48B 199M 172M 156M 149M 271M 18.35B 280M 1.86B 737M 8.77B 746M 730M 31.65B 68.18B 244M 212M 192M 183M 333M 22.55B 344M 2.28B 905M 10.78B 917M 897M 38.89B
Net income 262M 938K 814K 736K 702K 1.28M 86.59M 1.32M 8.75M 3.48M 41.37M 3.52M 3.44M 149M 5.23B 18.75M 16.27M 14.71M 14.04M 25.54M 1.73B 26.44M 175M 69.51M 827M 70.37M 68.87M 2.99B
Net Debt - -
Logo Abbott Laboratories (Pakistan) Limited
Abbott Laboratories Pakistan Limited is engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. The Company operates through four segments: Pharmaceutical, Nutritional, Diagnostic, and Others. It offers treatment options for a number of areas, including the digestive system, heart health, women’s health, respiratory illness, central nervous system/pain and influenza vaccines. Its nutritional brands include Similac, PediaSure, Pedialyte, Ensure, and Glucerna. It offers tests and diagnostic tools, medical diagnostic instruments, automation and informatics solutions for hospitals, reference labs, blood centers, emergency departments, physician offices and clinics. The Company’s easy-to-use test strips require only tiny blood samples while its meters provide results and reports.
Employees
1,406
Date Price Change Volume
26-03-12 852.10 -1.27% 7,664
26-03-11 863.09 -1.67% 63,393
26-03-10 877.77 +4.88% 27,660
26-03-09 836.92 -8.40% 35,788
26-03-06 913.66 -3.38% 5,632
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
852.10PKR
Average target price
1,300.00PKR
Spread / Average Target
+52.56%

Annual profits - Rate of surprise

SPRING SALE - 40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW